- Additional London-based clinic
to increase enrolment velocity
- Leading hospital with extensive cell therapy and oncology trial
experience
EDINBURGH, Scotland, Sept. 25,
2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK
Trial.
Guys and St. Thomas is a London-based hospital with a leading oncology
clinic and cell therapy clinical team. Dr. Hugues de Lavallade is the Principal
Investigator on the trial, having over 10 years of experience as a
consultant hematologist with a special interest in myeloid
disorders. This new site was opened in September 2024, facilitating the expedited
progression of the ACHIEVE clinical trial timelines using Dr. de
Lavallade's experience working with AML patients with measurable
residual disease.
"The progression of the ACHIEVE clinical trial since the dose
increase earlier this year continues to be very positive with
strong enrolment and remains on schedule for data in the first half
of 2025," said Alison Bracchi,
Executive Vice President of Clinical at TC BioPharm. "We are
thrilled with the positive feedback from Clinicians and the wider
AML community as we continue recruitment and activate new sites for
this important trial, and we feel fortunate to be partnering with
several centers of excellence to help us deliver on our goal of
offering new hope and an alternative treatment of seriously ill AML
patients."
The ACHIEVE UK clinical trial is an open-label, phase II study
designed to evaluate the efficacy and effectiveness of TCB008 in
patients with AML or MDS/AML, with either refractory or relapsed
disease.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the Company's intent or ability to affect any budget
savings or execute on any M&A or capital raising strategy.
These statements are based on management's current assumptions and
are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause the
Company's actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. For other important factors that could cause actual
results to differ materially from the forward-looking statements in
this Current Report on Form 8-K, please see the risks and
uncertainties identified under the heading "Risk Factors" in our
Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid
leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-site-opening-of-guys-and-st-thomas-hospital-302257464.html
SOURCE TC BioPharm
